Earth Science Tech, Inc. (OTC: ETST) Signs Marketing & Media Agreement with Pearls of Health and Appoints Gabriel Aviles as Chief Sales Officer (CSO).

Ft. Lauderdale, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company, which focuses on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce a recently signed media publicity and marketing agreement with the popular health talk radio show, Pearls of Health. Additionally, Gabriel Aviles the newly appointed Chief Sales Officer (CSO), expects 2017 to be a year of mass expansion for the company.

Pearls of Health has been on the air for 21 years and has amassed quite a following, both in its home state of Florida as well as abroad. The show Pearls of Health is well known for delivering unbiased and propaganda-free discussion on health products, research, and other health and wellness topics. The marketing agreement will include eight 40-minute interviews with guests of the company’s choosing, 104 minutes’ worth of commercials, and special placement on the station’s website and social media profiles. Additionally, the station intends to connect Earth Science Tech with several distributors, both internationally and domestically in hopes of creating and developing valuable business relationships with mutual benefits.

Gabriel Aviles, the new CSO has been working with the company since Q2 2016, and has proven himself by helping to get ETST products on store shelves all across the nation and in test phase in many chains across the country one being Lucky Vitamins as well many other chain stores that are in the final stages for PO (Purchase Order). Mr. Aviles will be leading and managing all sales channels for the company, including managing relationships with distributors, representatives across the country, and direct-to-consumer sales pipelines.

"I am excited to be part of this great organization and I am privileged to be part of ETST's management team,” said Mr. Aviles, “With such a rich history of selling high-quality nutritional supplements, this company has built up a strong brand name and immense trust with its customers. I think 2017 will be a tremendous year for this company, and I couldn’t be happier to be a part of the tight-knit team that’s going to make that happen.”

President, Director, and Chief Operating Officer, Nickolas S. Tabraue chimed in, “In 2016, we saw our products spread from just a few local stores to numerous stores across the country and growing. Gabriel, helped us accomplish this in just a short amount of time as he was only with us for part of the year. We anticipate that we will maintain our upward trajectory and I will be able to focus my energy on our planned new facility, partnerships, inventory control, and of course, our loyal investors. I am confident that 2017 will be the year we take ETST to the next level.”

About Earth Science Tech: 
Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases), as well developing new advanced formulated cannabis CBD nutraceuticals and 22 Cannabis CBD-based pharmaceutical drugs under its cannabis CBD patent, IP and technology. Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.



FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk facts that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.

CONTACT: Earth Science Tech, Inc.
(305)-615-2118
Nickolas S. Tabraue, P/D/COO

Investor Relations
(813)-500-7332
Teresa
Monday, January 9, 2017 - 07:45

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.